NL-OMON36269已完成2 期
Immunogenicity and safety of an adjuvant hepatitis B vaccine (fendrix) compared to Engerix in non-responding HIV-infected patients - Adjuvant hepatitis B vaccine in non-responding HIV infected patients
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Eligible patients must be on HAART, with HIV-RNA < 200 copies/ml and CD4+-cell counts > 200/ml and negative HBsAg, anti-HBc and anti-HBs titers.
排除标准
- •pregnancy, CD4 cell count < 200/ml, HCV co-infection, radiation therapy, cytotoxic agents, any immunemodulator
研究者
相似试验
进行中（未招募）
不适用
Immunogenicity and safety of an adjuvant hepatitis B vaccine (fendrix) compared to Engerix in non-responding HIV-infected patientsWe want to study the efficacy of Fendrix, a new adjuvant hepatitis B vaccin, in HIV infected patients, who failed to respond on intial standard and subsequent booster Hepatitis b vaccinations. We want to compare the efficacy of Fendrix to the efficacy of a double dose of the standard hepatitis b vaccinations, EngerixMedDRA version: 12.1Level: LLTClassification code 10002725Term: Anti-HIV positiveEUCTR2010-023946-58-NLErasmusMC
已完成
不适用
Evaluation of Immunogenicity and Safety of Hepatitis A Vaccine in AdolescentsCertain infectious and parasitic diseasesKCT0000407Ewha Womans University Medical Center300
已完成
1 期
Heptavalent Conjugate Vaccine against Pneumococcal (VCN7-T) in healthy infants and children.Pneumococcal infectionRPCEC00000173Biomolecular Chemistry Center (CQB)
已完成
1 期
Heptavalent Conjugate Vaccine against Pneumococcal in healthy adults (VCN7-T).Pneumococcal infection.RPCEC00000133Biomolecular Chemistry Center (CQB)40
进行中（未招募）
1 期
Safety and Efficacy of Neoadjuvant immunotherapy with Durvalumab (MEDI 4736) in combination with neoadjuvant chemotherapy (Gemcitabin/Cisplatin or Gemcitabin/Carboplatin) in patients with operable, high-risk, localized urothelial carcinoma of the upper urinary tract.The patient has a histologically-confirmed (ureteroscopic biopsy) or cytologically(urine cytology)-confirmed diagnosis of high-grade urothelial carcinoma of the renal pelvis or ureter. Presence of divergent histologies (i.e. squamous-cell tumor, adenocarcinoma, small cell carcinoma, micropapillary variant) may be acceptable provided that there is an important prevalence (> 90%) of urothelial component.MedDRA version: 20.0Level: LLTClassification code 10064467Term: Urothelial carcinomaSystem Organ Class: 100000004864EUCTR2020-001028-32-FRCHU DE NIMES99